Sepsis-related complications and mortality remain a major clinical problem. Increased cell death and unresolved cellular repair have been implicated as key upstream mediators of sepsis-induced organ dysfunction and death. We hypothesised that gene therapy with BRCA1, a critical regulator of DNA damage repair and cell survival, would attenuate the sequelae of sepsis and peritonitis in mice subjected to caecal ligation and perforation (CLP) and thioglycollate stimulation. C57Bl/6J mice underwent sham or CLP surgery 3 days following treatment with either human BRCA1 adenovirus (AdBRCA1) or the adeno-CMV-null vector (Adnull). The 24-h post-CLP mortality was 2.8% vs 17.9% (Po0.001) and the median post-CLP survival was 50.5 vs 33 h (Po0.05) for AdBRCA1-vs Adnull-treated mice, respectively. AdBRCA1 therapy blunted CLP-associated cardiac, pulmonary, hepatic and renal dysfunction and also reduced CLP-elicited double strand breaks and apoptosis in the liver. BRCA1 gene therapy was associated with lower CLP-evoked cardiac and hepatic superoxide generation that in the liver was in part due to improved reactive oxygen species removal. CLP also elevated mesenteric arteriolar and serum intercellular adhesion molecule-1, both of which were partially abrogated with AdBRCA1 administration. Thioglycollate-challenged AdBRCA1-treated mice displayed reduced peritoneal neutrophil recruitment and dampened cytokine elaboration relative to their Adnull-treated counterparts. Taken together, we report a novel role of BRCA1 gene therapy in limiting systemic inflammation, multiple-organ failure and mortality in experimental sepsis.
INTRODUCTION
Sepsis and its complications including systemic inflammatory response syndrome, and multiple organ dysfunction remain a major cause of morbidity and mortality worldwide.
1,2 Despite intensive research efforts and advancements in antimicrobial and anti-inflammatory therapies, clinical trials of conventional new drug targets have been disappointing and considerable residual risk persists in these patients. 1 --5 The pathophysiology of sepsis-related complications and mortality is multifactorial, 6 --9 and accumulating evidence suggests that activation of cell death pathways, with resultant increase in apoptosis, is a major contributor to the multiple organ dysfunction observed in experimental sepsis. 10 --13 Of note, experimental sepsis-associated cell death has been reported in cardiomyocytes, 14 hepatocytes, 15 thymocytes, 16 endothelial cells, 15, 17, 18 parenchymal cells 19 --21 and neutrophils, 22 whereas direct targeting of cell death pathways via gain-or loss-of-function approaches have been reported to markedly alter the septic phenotype. 11, 23 BRCA1 is a critical gatekeeper of genome stability and exerts multiple effects on key cellular processes involved in DNA repair, transcriptional regulation, ubiquitination and cell-cycle control. 24, 25 In addition to these recognised roles for BRCA1, emerging data suggest that BRCA1 also functions as an important mediator of innate immunity, 26 a central player in the pathophysiology of sepsis. Given the importance of BRCA1 in cellular defence, genome stability and immunosurveillance, we hypothesised that human BRCA1 gene delivery-based therapy would serve to limit systemic inflammation, multiple organ failure and mortality in experimental sepsis.
RESULTS

Adenoviral human BRCA1 gene delivery
We used green fluorescent protein (GFP) fluorescence as a means of determining optimal adenoviral delivery dosage. Graded GFP fluorescence was observed in the liver sections of mice treated with 10 10 PFU of the Adeno-CMV-null vector (Adnull), 10 8 PFU of Adeno-GFP (AdGFP) and 10 10 PFU of AdGFP ( Figure 1a ). PCR analyses confirmed human BRCA1 expression in hearts, livers, lungs and kidneys harvested from mice 3 days after administration of 10 8 PFU of the human BRCA1 adenovirus (AdBRCA1) and its absence in corresponding tissues from mice administered 10 8 PFU Adnull (Figure 1b ). Immunohistochemical staining of tissue sections corroborated these findings at the protein level (Figure 1c) . Accordingly, subsequent studies were performed in mice administered either 10 8 PFU Adnull or 10 8 PFU AdBRCA1.
Gene therapy with BRCA1 attenuates peritonitis-associated neutrophil transmigration and pro-inflammatory cytokine production To validate a role for BRCA1 in neutrophil homeostasis under normal versus pro-inflammatory conditions, we evaluated neutrophil recruitment in peritoneal lavage samples from Adnull-and AdBRCA1-treated mice challenged acutely (4 h) with thioglycollate. Thioglycollate treatment resulted in exaggerated neutrophil transmigration ( Figure 2a ) and a coincident increase in wholeblood neutrophil, monocyte and CD4 þ /CD8 þ T-cell ratios ( Figure 2b ). Neutrophil recruitment into the peritoneum of AdBRCA1-treated mice was less intense relative to that observed in their Adnull-treated counterparts (Figure 2a ). That animals within the phosphate-buffered saline (PBS) and thioglycollatetreated groups exhibited similar leukocyte differential profiles (Figure 2b ) suggests that the protective effects associated with AdBRCA1, at least in this acute scenario, were neither resultant of altered systemic neutrophil viability nor caused by changes in the relative composition of the leukocyte populations. As shown in Figure 3 , thioglycollate triggered substantial increases in serum chemokine (C-X-C motif) ligand 2 (CXCL-2), interferon (IFN)g, interleukin (IL)-6, monocyte chemoattractant protein (MCP)-1 and tumour necrosis factor (TNF), and these elevations were significantly attenuated in AdBRCA1-vs Adnull-treated mice. In contrast, mean serum levels of the anti-inflammatory cytokine IL-10 following thioglycollate challenge were higher in AdBRCA1-vs Adnull-treated mice ( Figure 3 ).
BRCA1 gene therapy markedly improves survival following caecal ligation and perforation (CLP) In order to determine if BRCA1 gene delivery would improve sepsis-induced mortality, we generated post-surgery Kaplan --Meier survival curves. We found that AdBRCA1 therapy markedly reduced CLP-associated mortality ( Figure 4) Figure 3 . BRCA1 gene therapy depresses serum concentrations of pro-inflammatory cytokines and enhances serum IL-10 levels in thioglycollate-challenged mice. Four hours after challenge with 1 ml of 3% thioglycollate (Thio) or 1 ml of PBS (i.p.), peripheral wholeblood samples were collected for sera cytokine profiling. n ¼ 8 per group for CXCL-2 and n ¼ 10 --12 per group for all other cytokines; *Po0.05 vs corresponding PBS-treated group; BRCA1 gene therapy attenuates the hypotensive and bradycardic effects of CLP We then proceeded to record mean arterial pressures, heart rates and locomotor activities using real-time telemetry. As shown in Table 1 , these parameters were similar across the board pre-sham/CLP surgery. However, while mean arterial pressures in the Adnull-treated CLP group fell continuously for 18 h post-CLP reaching a mean minimum of 63.1 mm Hg, mean arterial pressures in AdBRCA1-treated mice that underwent CLP reached a plateau of B80 mm Hg 8 h post-surgery and began slow recovery 7 h later ( Figure 5a ). The heart rates of mice that underwent CLP rose initially after surgery then continuously diminished before stabilising 10 --11 h later at 330 beats per minute for the Adnulltreated animals and 460 beats per minute for the AdBRCA1 group (Figure 5b) . Heart rates between the sham groups were similar (Figure 5b ). Locomotor activity following CLP was generally lower relative to that following sham surgery regardless of the adenoviral vector administered (Figure 5c ).
BRCA1 gene therapy impedes cardiac dysfunction evoked by CLP To assess the effects of CLP on cardiac function, we performed transthoracic two-dimensional echocardiography 24 h after surgery. Our measurements indicate significantly lowered left ventricle (LV) ejection fraction and fractional shortening in Adnull-treated mice that had been subjected to CLP relative to the Adnull-treated sham-operated group (Figure 6 ; Po0.05). Of note, AdBRCA1 treatment completely reversed the CLP-evoked decreases in LV ejection fraction and fractional shortening (Po0.05 vs Adnull-CLP group). BRCA1 gene therapy dampens CLP-associated increase in intercellular adhesion molecule-1 (ICAM-1) levels As shown in Figure 8a , while serum soluble ICAM-1 (sICAM-1) was appreciably elevated in mice that had received Adnull before undergoing the CLP procedure, this rise was blunted in samples from those that were treated with AdBRCA1 before having CLP surgery. Furthermore, CLP significantly enhanced ICAM-1 levels in en face preparations of first order mesenteric arterioles and this increment was markedly lower in AdBRCA1-treated mice that underwent the CLP procedure ( Figure 8b ).
BRCA1 gene therapy decreases double strand breaks and abrogates apoptosis in the liver Livers from mice that were administered Adnull before CLP exhibited the highest levels of gH2A.X (marker of double strand breaks; Figure 9a ), greatest total caspase-3 content (indicator of apoptosis; Figure 9b ) and highest Bax/Bcl-2 ratios (index of apoptosis; Figure 9c ). AdBRCA1 treatment reduced the impact that CLP had on these indices of cell death ( Figure 9 ).
BRCA1 gene therapy inhibits CLP-associated increase in intracellular superoxide generation To determine if BRCA1 gene delivery affects intracellular reactive oxygen species (ROS) production, we recorded topolocalisation of red fluorescent punctate nuclear staining resulting from the irreversible binding of ethidium to double-stranded DNA to evaluate superoxide elaboration. CLP surgery was associated with intensified ethidium staining in heart and liver sections and semi-quantitative analysis revealed less ethidium-positive signals in sections from the AdBRCA1-treated CLP group compared with sections from the corresponding Adnull-treated animals ( Figure 10 ).
As the decreases in DHE positivity observed with BRCA1 gene therapy may be attributed to either a reduction in ROS generation or improved detoxification of ROS, or indeed a combination of both, we measured in liver samples, protein expression of the antioxidant Cu/Zn superoxide dismutase (SOD1) and nuclear abundance of nuclear factor erythroid 2-related factor 2 (Nrf2), a transcriptional regulator of multiple genes involved in antioxidant defence and a downstream target of BRCA1. 27 While liver SOD1 levels were significantly lower in Adnull-treated, CLP-operated mice, this reduction was notably absent in liver samples from mice that had been injected with AdBRCA1 before undergoing CLP surgery ( Figure 11a ). Paradoxically, nuclear accumulation of Nrf2 in the liver was appreciably reduced following CLP surgery ( Figure 11b ) and this coincided with downregulation of Nrf2-driven expression of the NQO1, GPX2 and GSTA2 genes ( Figure 11c ). The impaired stabilisation of Nrf2 as well as the decreased induction of the NQO1, GPX2 and GSTA2 genes were unaffected by BRCA1 gene therapy.
DISCUSSION
Sepsis is a multifactorial disease in which inflammation, insufficient and inappropriate immune response, increased neutrophilendothelial activation, augmented ROS production and multiple organ apoptosis have been identified as key pathogenic factors. 6 --9 The unbridled cytokine storm that occurs early on in sepsis serves as an important trigger of death signals via NF-kB and Fas 28 --31 and also promotes cell cycle arrest of immune cells, with resultant apoptosis. Compelling evidence to date implicate a role for multiple organ apoptosis and activation of cell-death pathways in experimental sepsis 8, 10 by both the intrinsic and extrinsic apoptotic pathways. 32 Increased apoptosis of both T and B lymphocytes is observed in human sepsis, 33 as well as in thymic, splenic and bone marrow-derived T-cell populations after experimental sepsis. 8 Elevations in epithelial cell apoptosis has been linked to alteration of mesenteric and lung dysfunction in severe sepsis. 19 --21 Endothelial activation and apoptosis has also been suggested as a common effector of organ dysfunction in sepsis and contributes to sepsis-induced microvascular disease and vascular collapse. Given the importance of multi-organ cell death in the pathophysiology of sepsis, it follows that strategies aimed at inhibiting cell death pathways may serve to inhibit systemic inflammation and resultant organ dysfunction in sepsis. In this regard, recent studies have demonstrated that administration of the anti-apoptotic protein Bcl-2 protects mice from sepsis by promoting multi-organ cell survival.
11
BRCA1 performs a critical role in the maintenance of genome stability where it functions as a caretaker of the genome. 34 It is fundamental to a variety of cell-survival pathways that regulate DNA break repair, transcriptional regulation, ubiquitination and cell cycle control. BRCA1 further exhibits pleiotropic cellular protection through activation of diverse cellular processes and has been implicated as a mediator of G2/M checkpoint arrest in response to DNA damage, while other studies suggest that it may also function as a checkpoint mediator similar to Mdc1, 53BP1 and claspin. 34 Aside from modulating gene transcription, BRCA1 has also been linked to chromatin remodelling, regulation of p53 and more recently as a modulator of immune surveillance and innate immunity. 35 In consideration of the diverse roles of BRCA1 in regulating cell survival, it is an attractive target to evaluate as potential therapy, particularly in diseases characterised by widespread activation of cell-death signals. In this regard, recent data suggest that BRCA1 may serve as an important regulator of 36 Furthermore, AdBRCA1 gene therapy has been shown to limit the development of atherosclerosis in ApoE-deficient mice. 36 We report a novel protective role for BRCA1 gene therapy in multiple organ injury and survival triggered by polymicrobial infection and in acute inflammation induced by sterile peritonitis. Naïve mice administered AdBRCA1 3 days before CLP demonstrated, relative to their Adnull-treated counterparts, profoundly lower short-and long-term mortality. There was evidence of significant protection from sepsis-induced multiple organ dysfunction such that AdBRCA1-treated animals exhibited better haemodynamic, cardiac, pulmonary, hepatic and renal function in comparison to their Adnull-treated littermate controls. In the liver, this benefit stemmed from improved cell viability, specifically apoptosis, as BRCA1 gene therapy was associated with reduced double strand breaks, less total caspase-3 content and lower Bax/Bcl-2 ratios. The effects of BRCA1 to limit sepsis-related organ dysfunction were also associated with a downregulation of pro-inflammatory CXCL-2, IFNg, IL-6, MCP-1 and TNF, and upregulation of the anti-inflammatory cytokine IL-10 with reduced expression of ICAM-1, suggesting overall improvement in neutrophil --endothelial homeostasis. These data point towards a marked and pleiotropic anti-inflammatory response of BRCA1 in experimental sepsis.
A cardinal component of the normal host defence is the generation of ROS by leukocytes. 37 ROS accumulation, as a result of either ROS overproduction or impaired ROS clearance, can compromise the integrity and function of the endothelial barrier. This can in turn cause tissue oedema and acceleration of leukocyte extravasation as well as detrimental cytoskeletal reorganisations amongst other derangements that can culminate in tissue necrosis and are the hallmarks of many chronic diseases. 38 Importantly, cumulative evidence from both animal models of sepsis 39, 40 and patients with sepsis 41, 42 support the notion that ROS-mediated subcellular and cellular damage are primary causes of sepsis-associated dysfunction, presumably via augmenting DNA damage. Recently, in a murine model of inflammatory bowel disease, BRCA1 upregulation was accompanied by enhanced antioxidant activity and reduced ROS in the colon mucosa, 43 an observation that is consistent with our findings of reduced CLPinduced superoxide production in AdBRCA1-treated animals. The current work extends these findings by demonstrating that part of the protection afforded by BRCA1 gene therapy is rooted in improved antioxidant-mediated detoxification.
The reduced Nrf2 activity that we observed in the face of elevated oxidative stress was unexpected. This phenomenon, however, has been reported previously in both clinical and animal models of other inflammatory-based diseases, which include chronic obstructive pulmonary disease, emphysema and chronic kidney disease. 44 --47 Indeed, this defect in the Nrf2 system and the ensuing failure to orchestrate the appropriate defensive responses may be critical in perpetuating an environment that is already under significant oxidative stress and could in turn advance the inflammatory milieu and promote cell death culminating in tissue damage and organ failure. In our model, the benefits of BRCA1 appeared to be independent of the Nrf2 network, a downstream target and effector of BRCA1-mediated events. 27 We caution, however, that as we only studied one post-CLP time point, we are unable to speculate with the current set of data whether BRCA1 would act differently and via Nrf2 in different settings of sepsis, and this line of thought remains to be explored.
Taking into account the available findings, we propose that BRCA1 gene therapy contains sepsis and peritonitis-triggered cytokine storms, dampens oxidative stress and suppresses the concomitant increases in adhesion molecule expression. These events serve to subsequently lessen the propensity of leukocyte recruitment and markedly reduce mortality from experimental sepsis. These data suggest a novel and previously unrecogised role of BRCA1 treatment as a potential global anti-inflammatory therapy in experimental sepsis.
Sepsis is a clinical and pathological continuum that involves intricate cell --cell and mediator --mediator interactions with a mosaic of cell death modalities co-existing at any one time. 48 As such, it is likely that only specific cell subpopulations may benefit from different therapeutic strategies or the introduction of targeted therapy at different time points. Nevertheless, from a therapeutic standpoint, our data suggest that BRCA1-based gene therapy may be a novel treatment approach to limit sepsisinduced inflammation, multi-organ failure and death. From a genomic standpoint, our data may suggest that individuals who carry loss-of-function mutations in BRCA1 may be predisposed to higher rates and severity of sepsis-related complications, a speculative hypothesis that requires clinical validation. Of note, BRCA1 has recently been reported to be an essential regulator of heart function and survival following myocardial infarction. 49 As individuals with BRCA1 mutations often develop cancer syndromes and may be immunocompromised, particularly if treated with chemotherapy, it may be of interest to evaluate whether there is a difference in susceptibility to sepsis in such patients.
MATERIALS AND METHODS
Animals and adenovirus treatment
All procedures adhered to the guidelines of the Canadian Council on Animal Care and were approved by the institutional Animal Care Committee. Studies were performed on male (8 --10 weeks old) C57Bl/6J mice (The Jackson Laboratory, Bar Harbor, ME, USA) housed in a climatecontrolled (temperature 22 --24 1C, humidity 40 --60%), light-regulated room with a 12-h light:12-h dark cycle. Each cage accommodated up to five mice and was ventilated at 60 ACH. Mice were maintained on irradiated Teklad Global 18% Protein Rodent Diet pellets (Harlan Laboratories, Mississauga, ON, Canada) and had ad libitum access to reverse osmosis water throughout the acclimatisation and study windows.
At 3 days after tail vein administration of AdGFP, Adnull or AdBRCA1 (all from Vector Biolabs, Philadelphia, PA, USA), all of which were driven by the CMV promoter, mice were randomised to one of two study models. The custom-designed AdBRCA1 contained the complete coding sequence of human BRCA1 (accession no. NM_007294.2).
Peritonitis (thioglycollate) model
Mice were randomised to receive either 1 ml of 3% thioglycollate (BD Difco, Mississauga, ON, Canada) or an equivolume of modified PBS (i.p.). Four hours later, mice were euthanised for sample collection.
Sepsis (CLP) model
Anaesthetised (2% isoflurane) mice underwent o1 cm midline laparotomies and were randomised to either the sham or the CLP group. Caecums were ligated B0.5 cm distal to the ileocaecal valves and each caecal stump was subjected to a single 'through-and-through' puncture with an 18-ga needle. Caecums were returned to the peritoneal cavities and the incisions closed with dual layers of running sutures. The ligation and perforation steps were omitted in the otherwise identically shamoperated group. All the mice received fluid resuscitation (1 ml saline, s.c. 
Echocardiography
Transthoracic two-dimensional echocardiography was performed on anaesthetised mice (1 --1.5%. isoflurane) 24 h after undergoing the sham or CLP procedure. Imaging, performed in the parasternal long-and shortaxis views, was completed by a single investigator blinded to the treatment groups using an HDI 5000cv echocardiographic system (Philips Healthcare, Andover, MA, USA) coupled to a compact 15 MHz broadband linear transducer (CL15-7). An M-mode cursor was positioned perpendicular to the interventricular septum and posterior wall of the LV at the level of the papillary muscles, and M-mode images were obtained for measurement of chamber dimensions throughout the cardiac cycle. LV end-diastolic (LVEDD) and LV end-systolic (LVESD) dimensions were assessed. During diastole, LV dimension and wall thickness were measured from the maximum chamber cavity; during systole, they were measured during maximum anterior motion of the posterior wall. The functional parameters, ejection fraction and fractional shortening, were averaged from three independent and representative cardiac cycles and defined as ((LVEDD  3 -LVESD   3 )/LVEDD 3 ) Â 100 and ((LVEDD-LVESD)/LVEDD) Â 100, respectively.
Haematological tests, ICAM-1 ELISA and flow cytometry Peritoneal cavities and the lungs were lavaged with 4 ml and 3 Â 1 ml, respectively, of ice-cold-modified PBS (containing 1% bovine serum albumin and 5 mM EDTA). Whole-blood samples were obtained via cardiac puncture. Sera were collected from blood samples that were allowed to clot at room temperature for 30 min. Sera from the peritonitis group of animals were frozen for blinded quantitation of IL-6, IL-10, IFNg, MCP-1 and TNF using a multiplex bead-based immunoassay (BD CBA Flex Set, BD Biosciences, Mississauga, ON, Canada) and of CXCL-2 with a commercially available ELISA kit (R&D, Minneapolis, MN, USA). Aliquots of sera from sham-or CLP-operated animals were either analysed by an independent animal diagnostics facility (IDEXX Laboratories, Markham, ON, Canada) within 12 h for proteins associated with hepatic and renal function or frozen for subsequent evaluation of sICAM-1 with a commercially available ELISA kit (R&D). For determination of leukocyte subpopulations, samples of whole-blood collected in EDTA, peritoneal lavage and bronchiolar lavage were pre-incubated with BD Fc Block (Rat anti-mouse CD16/CD32) and the appropriate antibody cocktails added: APC conjugated anti-CD45 (clone 30-F11), FITC conjugated anti-CD3 (clone 17A2), PE-conjugated anti-CD19 (clone 1D3), PerCP-Cy5.5 conjugated anti-CD4 (clone RM4-5) and PE-Cy7 conjugated anti-CD8a (clone 53-6.7) to identify lymphoid subpopulations; APC conjugated anti-CD45 (clone 30-F11), FITC conjugated anti-Gr-1 (clone RB6-8C5), PE conjugated anti-Neutrophil (clone 7/4, AbD Serotec) and PerCP-Cy5.5 conjugated anti-CD11b (clone M1/70) to identify myeloid subpopulations in whole-blood samples; APC conjugated anti-CD45 (clone 30-F11), FITC conjugated anti-Gr-1 (clone RB6-8C5) and PE conjugated antiNeutrophil (clone 7/4) to identify myeloid subpopulations in peritoneal lavage samples; or APC conjugated anti-CD45 (clone 30-F11), APC-Cy7 conjugated anti-Gr-1 (clone RB6-8C5), PE conjugated anti-F4/80 (CI:A3-1, AbD Serotec) and PE-Cy7 conjugated CD11c to identify myeloid subpopulations in bronchiolar lavage samples. Thereafter, erythrocytes in the whole-blood samples were lysed with the FACSLyse reagent, whereas an aliquot of CountBright absolute counting beads (Molecular Probes, Burlington, ON, Canada) and 7-AAD (Invitrogen) were added to the peritoneal and bronchiolar lavage samples to enumerate absolute neutrophil and macrophage counts and evaluate cell viability. Data from the peritoneal and bronchiolar lavage samples were normalised against the total sample volumes that fell in the range of 2.3 --4.9-ml and 2.2 --4.3-ml, respectively. The whole-blood immunophenotyping method yielded CD45 by side scatter (SSC) profiles similar to those of normal human peripheral leukocytes. Parallel analyses were performed in every sample with the corresponding fluorochrome-conjugated isotype controls. Data were acquired on the FACSCanto II and the FACSArray (BD Biosciences). Unless otherwise stated, all flow cytometry reagents and antibodies were purchased from BD Biosciences.
Immunofluorescence
Hearts and liver lobes from AdGFP-, Adnull-or AdBRCA1-treated animals were harvested, snap-frozen in OCT and sectioned (5 mm). Tissue sections from mice treated with Adnull or AdBRCA1 were fixed in cold acetone and incubated with 20 mM of the oxidation-dependent fluorescent dye dihydroethidium (DHE; Sigma, St Louis, MO, USA) or an equivolume of the DHE diluent (0.07% DMSO in PBS) in a light-protected humidified chamber at 37 1C for 30 min. Ethidium-positive punctate nuclear stained areas were quantified by dividing the sum of the stained areas with the total cross-sectional area of the tissue section. GFP (green) and ethidium (red) fluorescence was visualised under a Nikon fluorescence microscope.
Cleaned first-order mesenteric arterioles were perfuse-fixed in 2% paraformaldehyde at 60 mm Hg for 30 min. En face preparations were blocked with normal donkey serum (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), incubated with an antibody directed against ICAM-1 (R&D) or an equivolume of the blocking serum, probed with an Alexa Fluor 488 secondary antibody (Invitrogen), stained with TOPRO-3 (Invitrogen) and imaged by confocal microscopy with a Bio-Rad Radiance 2100 Laser Scanning System coupled to a Nikon Eclipse E800 microscope. Z-scans in 2 mm increments were projected using the LaserSharp 2000 software (ver. 4.3; Bio-Rad, Mississauga, ON, Canada).
In all instances, laser and power settings were identical during acquisition of images. Three blinded observers independently analysed the signal strength in each microtoprograph using the ImageJ software (http://rsb.info.nih.gov/ij/). Measurements were averaged to obtain a single value for each animal and data from the animals in each group were averaged to obtain a single value for statistical analysis.
Immunohistochemistry
For BRCA1 immunostaining, mice were intracardially bled and ice-cold PBS injected into the LV to flush out any remaining blood. Hearts, livers, lungs and kidneys were fixed under pressure with 4% paraformaldehyde, isolated, immersed in 4% paraformaldehyde overnight at 4 1C, and embedded in paraffin for sectioning (5 mm). Following incubation with a mouse anti-BRCA1 antibody clone MS110, Calbiochem, Billerica, MA, USA), sections were immunostained with the VECTASTAIN Elite ABC kit, counterstained with methyl green and visualised with a VIP substrate (Vector Laboratories, Burlington, ON, Canada). Negative control experiments were performed with the corresponding normal IgG.
Western blot
Total protein from snap-frozen liver lobes were extracted with the Invitrogen Tissue Extraction Reagent in the presence of a protease inhibitor (Sigma) and quantified with the Bio-Rad DC Protein Assay Reagent. Lysates were separated by SDS-PAGE, electrotransferred to nitrocellulose membranes and probed with rabbit-derived antibodies directed at Bax, Bcl-2, total caspase-3, phospho-histone H2A.X (Ser139), SOD1 or a/ß-tubulin (all from Cell Signaling, Pickering, ON, Canada). Following incubation with a horseradish peroxidase-conjugated donkey anti-rabbit antibody (GE Healthcare, Piscataway, NJ, USA), signals were visualised with either the Amersham ECL Plus system (GE Healthcare) or the Immun-Star WesternC Chemiluminescence system (Bio-Rad).
Nrf2 activity assay
Liver nuclear proteins were isolated with the Active Motif Nuclear Extract Kit (Active Motif, Carlsbad, CA, USA) and quantified with the Bio-Rad Protein Assay Reagent. Nrf2 activity was determined with the colorimetric reaction-based TransAM Nrf2 kit (Active Motif) as per the manufacturer's instructions. Experiments were performed in triplicates.
Statistical analyses
Survival curves were created with the product limit method of Kaplan and Meier and compared with the log rank test. Telemetry and Nrf2 activity results are expressed as means ± s.e. for n number of animals. All other data are presented as medians (means as dotted lines) with interquartile range. Cytokine data underwent logarithmic transformations prior to analysis. Differences between multiple means were evaluated by one-way ANOVA, and when overall differences were detected, individual means were compared post-hoc with the Bonferroni's test. Statistical significance was considered achieved at Po0.05.
